- Conditions
- Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
- Interventions
- Itolizumab, EQ001 Placebo
- Biological · Drug
- Lead sponsor
- Equillium
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute-graft-versus-host Disease, aGVHD, GVHD, GVHD, Acute
- Interventions
- EQ001, EQ001 Placebo
- Biological
- Lead sponsor
- Biocon Limited
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 16
- States / cities
- Duarte, California • Gainesville, Florida • Miami, Florida + 13 more
- Conditions
- Lupus Erythematosus, Lupus Nephritis
- Interventions
- Itolizumab [Bmab 600]
- Drug
- Lead sponsor
- Biocon Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 19
- States / cities
- Sun City, Arizona • Chula Vista, California • La Jolla, California + 14 more